Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure

被引：38

作者：

Guazzi, Marco ^{[1
]}

机构：

[1] Univ Milan, Heart Failure Unit, Cardiopulm Lab, San Paolo Hosp,Dept Med & Surg, I-20142 Milan, Italy

来源：

CIRCULATION-HEART FAILURE | 2008年 / 1卷 / 04期

关键词：

heart failure; pharmacology;

D O I：

10.1161/CIRCHEARTFAILURE.108.802116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：272 / 280

页数：9

共 71 条

[1] The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure [J].

Al-Hesayen, Abdul ;

Floras, John S. ;

Parker, John D. .

EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (08) :864-868

[2] Development of a ventilatory classification system in patients with heart failure [J].

Arena, Ross ;

Myers, Jonathan ;

Abella, Joshua ;

Peberdy, Mary Ann ;

Bensimhon, Daniel ;

Chase, Paul ;

Guazzi, Marco .

CIRCULATION, 2007, 115 (18) :2410-2417

[3] Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes [J].

Ballard, SA ;

Gingell, CJ ;

Tang, K ;

Turner, LA ;

Price, ME ;

Naylor, AM .

JOURNAL OF UROLOGY, 1998, 159 (06) :2164-2171

[4] Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure:: A double-blind, placebo-controlled clinical trial [J].

Behling, Alice ;

Rohde, Luis E. ;

Colombo, Fernanda C. ;

Goldraich, Livia A. ;

Stein, Ricardo ;

Clausell, Nadine .

JOURNAL OF CARDIAC FAILURE, 2008, 14 (03) :189-197

[5] Sildenaril effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure - A double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction [J].

Bocchi, EA ;

Guimaraes, G ;

Mocelin, A ;

Bacal, F ;

Bellotti, G ;

Ramires, JF .

CIRCULATION, 2002, 106 (09) :1097-1103

[6]

Boolell M, 1996, Int J Impot Res, V8, P47

[7] Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans [J].

Borlaug, BA ;

Melenovsky, V ;

Marhin, T ;

Fitzgerald, P ;

Kass, DA .

CIRCULATION, 2005, 112 (17) :2642-2649

[8] Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED [J].

Boyle, CD ;

Xu, R ;

Asberom, T ;

Chackalamannil, S ;

Clader, JW ;

Greenlee, WJ ;

Guzik, H ;

Hu, YQ ;

Hu, ZY ;

Lankin, CM ;

Pissarnitski, DA ;

Stamford, AW ;

Wang, YG ;

Skell, J ;

Kurowski, S ;

Vemulapalli, S ;

Palamanda, J ;

Chintala, M ;

Wu, P ;

Myers, J ;

Wang, P .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (09) :2365-2369

[9] A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST) [J].

Califf, RM ;

Adams, KF ;

McKenna, WJ ;

Gheorghiade, M ;

Uretsky, BF ;

McNulty, SE ;

Darius, H ;

Schulman, K ;

Zannad, F ;

HandbergThurmond, E ;

Harrell, FE ;

Wheeler, W ;

SolerSoler, J ;

Swedberg, K .

AMERICAN HEART JOURNAL, 1997, 134 (01) :44-54

[10] Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure [J].

Chen, YJ ;

Traverse, JH ;

Hou, MX ;

Li, YF ;

Du, RS ;

Bache, RJ .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2003, 284 (05) :H1513-H1520

← 1 2 3 4 5 6 7 8 →